RxDoctor Payments Data

Keolamau Yee, MD

Internal Medicine · Aiea, HINPI 1922569441

Payments from drug & device makers

$3,985in general payments, 2019–2025

Across 226 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$587
  • Novo Nordisk$539
  • GSK$501
  • Boehringer Ingelheim$409
  • Lilly USA, LLC$375
  • AstraZeneca$359
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,985 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$127,275
Medicare patients
429
Services billed
1,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$231,811
RybelsusSemaglutide90$191,022
OzempicSemaglutide85$150,628
MounjaroTirzepatide58$97,686
VascepaIcosapent Ethyl90$63,686
EliquisApixaban37$45,527
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$38,649
Soliqua 100-33Insulin Glargine/Lixisenatide18$33,293
JanuviaSitagliptin Phosphate22$32,436
FarxigaDapagliflozin Propanediol26$31,143
Atorvastatin Calcium566$16,561
BrilintaTicagrelor11$10,620
Colesevelam Hcl16$8,661
Wixela InhubFluticasone Propion/Salmeterol61$7,126
Losartan Potassium369$7,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$539$341,650175 claims
Boehringer IngelheimJardiance$409$231,811152 claims
Lilly USA, LLCMounjaro$375$97,68658 claims
PfizerEliquis$138$45,52737 claims
AstraZenecaFarxiga, Brilinta$359$41,76337 claims
GSKTrelegy Ellipta$501$38,64936 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$38$33,29318 claims
MerckJanuvia$107$32,43622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →